Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 1/20 | 0.74 |
| ▸ | DHODH | Q02127 | 12/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metanixin SCHEMBL2107737 | 0.90 | LMNA (0.78) | CLCN2DHODHLMNAGAAMEN1 | |
| SCHEMBL24021545 | 0.85 | CLCN2 (1.00) | CLCN2DHODHLMNAGAAMEN1 | |
| SCHEMBL11837738 | 0.84 | HTT (0.54) | CLCN2DHODHLMNAGAARAB9A | |
| Clonixin SCHEMBL121785 | 0.81 | DHODH (1.00) | CLCN2DHODHLMNAGAAMEN1 | |
| Clonixin SCHEMBL30702579 | 0.81 | DHODH (1.00) | CLCN2DHODHLMNAGAAMEN1 | |
| Clonixin SCHEMBL9143637 | 0.81 | DHODH (1.00) | CLCN2DHODHLMNAGAAMEN1 | |
| SCHEMBL5572440 | 0.78 | CLCN2 (0.63) | CLCN2DHODHLMNAGAAMEN1 | |
| SCHEMBL28785117 | 0.78 | ACLY (0.54) | CLCN2LMNAMEN1KMT2AMAPT | |
| Nixylic Acid SCHEMBL31016400 | 0.78 | DHODH (0.76) | CLCN2DHODHLMNAGAAMEN1 | |
| Nixylic Acid SCHEMBL2733856 | 0.78 | DHODH (0.76) | CLCN2DHODHLMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024229332-A1 | ANTI-CANCER TREATMENTS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024229332-A1 | ANTI-CANCER TREATMENTS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | disclosed |
| EP-0105635-B1 | NONIRRITATING AQUEOUS OPHTHALMIC COMPOSITIONS COMFORT FORMULATION FOR OCULAR THEREPEUTIC AGENTS | ALCON LABORATORIES, INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | disclosed |
| US-4559343-A | ANTIINFLAMMATORY AGENT WITH XANTHINE DERIVATIVE | ALCON LABORATORIES, INC. (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0105635-A2 | Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therepeutic agents | ALCON LABORATORIES, INC. (US) | 1984-04-18 | — | — | EP | disclosed |
| US-3959272-A | ANALGESICS, ANTIINFLAMMATORY, PSYCHOTROPIC | SOCIETE ANONYME DITE: HEXACHIME (FR) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | CLCN2 4571/4885DHODH 526/4885LMNA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.